Respiratory Emergency Medicine Moderate — validated in MIST2 RCT cohort
RAPID Score for Pleural Infection
Predicts 3-month mortality in patients with pleural infection (empyema/complicated parapneumonic effusion) to guide management intensity. Validated in the MIST2 trial cohort.
References
- Rahman NM, et al. A clinical score (RAPID) to identify those at risk for poor outcome at presentation in patients with pleural infection. Chest. 2014;145(4):848–855.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Tolfenamic acid · NSAID (anthranilic acid)
- Insulin Aspart · Rapid-Acting Insulin Analogue (Bolus)
- Insulin Lispro · Rapid-acting Insulin Analogue
- Insulin Glulisine · Rapid-acting Insulin Analogue
- Insulin aspart · Rapid-acting analogue insulin
Pathways
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- COPD Exacerbation Management · NICE NG115 / GOLD 2024
- Community-Acquired Pneumonia (CURB-65) · BTS 2009 / NICE NG138
- Acute Pulmonary Embolism · BTS 2003 / ESC 2019
- Pleural Effusion Assessment · BTS 2010
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.